

Penbraya[™] (meningococcal groups A, B, C, W, and Y vaccine) – New vaccine approval

- On October 20, 2023, <u>Pfizer announced</u> the FDA approval of <u>Penbraya (meningococcal groups A, B, C, W, and Y)</u>, for active immunization to prevent invasive disease caused by *Neisseria meningitidis* serogroups A, B, C, W, and Y.
 - Penbraya is approved for use in individuals 10 through 25 years of age.
- Penbraya is the first pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age.
- The efficacy of Penbraya was established in a randomized, active-controlled, observer-blinded study in participants 10 through 25 years of age. Patients received Penbraya at 0 and 6 months or <u>Trumenba® (meningococcal group B vaccine)</u> at 0 and 6 months and MenACWY-CRM at 0 months.
 - Seroresponse rates to serogroups A, C, W, and Y following 2 doses of Penbraya were demonstrated to be non-inferior to seroresponse rates following a single dose of MenACWY-CRM. Seroresponse and composite response rates to serogroup B primary strains among participants who received 2 doses of Penbraya were demonstrated to be non-inferior to seroresponse and composite response rates following 2 doses of Trumenba.
- The CDC Advisory Committee on Immunization Practices (ACIP) will meet on October 25, 2023, to discuss recommendations for the appropriate use of Penbraya in adolescents and young adults.
- Warnings and precautions for Penbraya include management of acute allergic reactions; syncope; altered immunocompetence; limitations of vaccine effectiveness; tetanus immunization; and Guillain-Barré syndrome.
- The most commonly reported solicited adverse reactions (≥ 15%) with Penbraya use were pain at the injection site, fatigue, headache, muscle pain, injection site redness, injection site swelling, joint pain, and chills.
- Penbraya is administered as 2 doses (approximately 0.5 mL each) intramuscularly 6 months apart.
- Pfizer's launch plans for Penbraya are pending. Penbraya will be available as a suspension for injection. A single dose after reconstitution is approximately 0.5 mL.

Optum

At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.